Clinical trial / 2013
A 4% isoflavone vaginal gel relieved vaginal atrophy symptoms and improved vaginal cell maturation values in postmenopausal women over 12 weeks.
Ninety postmenopausal women were randomized to receive 4% isoflavone vaginal gel (1 g/day), placebo gel, or conjugated equine estrogen cream (0.3 mg/day) for 12 weeks. Isoflavone vaginal gel was effective for relieving vaginal dryness and dyspareunia symptoms and increased intermediate and superficial cells, showing results similar to conjugated equine estrogens and superior to placebo. No changes in endometrial thickness, serum FSH, or estradiol levels were observed at the study endpoint.
- Study type
- Double-blind, randomized, placebo-controlled clinical trial
- Who was studied
- 90 postmenopausal women
- What was measured
- Vaginal atrophy symptoms, vaginal cytology maturation value, and endometrial safety
THE PAPER
Effective treatment of vaginal atrophy with isoflavone vaginal gel.
Lima SM, Yamada SS, Reis BF, Postigo S, Galvão da Silva MA, Aoki T. Maturitas, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.